554720

反式-维甲酸

Potent modulator of growth and differentiation. Inhibits melanocyte adhesion, motility, and growth.

• 同義詞: 反式-维甲酸, 维甲酸，ATRA，维生素A酸
• 經驗公式（希爾表示法）: C₂₀H₂₈O₂
• CAS號碼: 302-79-4
• 分子量：: 300.44
• MDL號碼: MFCD00001551
• 分類程式碼代碼: 12352106
• NACRES: NA.21

屬性

• 品質等級: 100
• 化驗: ≥95% (by assay)
• 形狀: solid
• 製造商／商標名: Calbiochem^®
• 儲存條件: OK to freeze; desiccated (hygroscopic); protect from light
• 顏色: yellow
• 溶解度: DMSO: 25 mg/mL
• 運輸包裝: ambient
• 儲存溫度: 2-8°C
• InChI: 1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+
• InChI 密鑰: SHGAZHPCJJPHSC-YCNIQYBTSA-N

描述

一般說明

生长和分化的有效调节剂。通过与直接调节基因表达的核视黄酸受体（RAR）结合发挥作用。抑制黑素细胞粘附、运动和生长。具有角膜溶解活性。诱导神经源性肿瘤细胞分化。诱导急性早幼粒细胞癌细胞凋亡。

生长和分化的有效调节剂。通过与直接调节基因表达的核视黄酸受体（RAR）结合发挥作用。抑制黑素细胞粘附、运动和生长。具有角膜溶解活性。诱导神经源性肿瘤细胞分化。诱导急性早幼粒细胞癌细胞凋亡。避免空气。

應用

• All-trans-retinoic acid modulates glycolysis via H19 and telomerase: the role of mir-let-7a in estrogen receptor-positive breast cancer cells.: This research reveals how all-trans-retinoic acid influences glycolysis in breast cancer cells by modulating H19 and telomerase, demonstrating its potential in breast cancer therapy (El Habre et al., 2024).


• Retinoic acid tiers mitochondrial metabolism to Sertoli Cell-Mediated efferocytosis via a non-RAR-dependent mechanism.: The study explores the role of retinoic acid in linking mitochondrial metabolism to efferocytosis in Sertoli cells, providing insights into its non-RAR-dependent mechanisms and potential applications in reproductive biology (Wu et al., 2024).


• Combined treatment of All-trans retinoic acid with Tamoxifen suppresses ovarian cancer.: This article discusses the synergistic effects of combining all-trans-retinoic acid with tamoxifen in suppressing ovarian cancer, highlighting a promising therapeutic strategy for ovarian cancer patients (Xu et al., 2024).

包裝

用惰性气体包装

警告

毒性：有害 & 致癌/致畸性（E）

重構

复溶后冷藏（4°C）。DMSO贮备溶液在4°C下可稳定保存最多2年。

其他說明

Tosi, P., et al. 1994.Leuk.Lymphoma14, 503.
Clagett-Dame, M., et al. 1993.Arch.Biochem.Biophys.300, 684.
Labbaye, C., et al. 1993.Blood81, 475.
Sakashita, A., et al. 1993.Blood81, 1009.
Situ, R., et al. 1993.Dermatology186, 38.
Tini, M., et al. 1993.Genes Develop.7, 295.
Leid, M., et al. 1992.Trends Biochem.Sci.17, 427.
Sharpe, C.R.1991.Neuron7, 239.
Thaller, C. and Eichele, G. 1990.Nature345, 815.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

安全資訊

• 象形圖: GHS08,GHS07,GHS09
• 訊號詞: Danger
• 危險聲明: H302,H315,H360FD,H410
• 防範說明: P202 - P264 - P273 - P301 + P312 - P302 + P352 - P308 + P313
• 危險分類: Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 1B - Skin Irrit. 2
• 儲存類別代碼: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• 水污染物質分類（WGK）: WGK 2
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable